- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Dr Landgren on the Utility of Tocilizumab Prophylaxis in Relapsed/Refractory Multiple Myeloma
C. Ola Landgren, MD, PhD, discusses tocilizumab prophylaxis in relapsed/refractory myeloma treated with teclistamab, elranatamab, or talquetamab.
- 2x
- 1.75x
- 1.5x
- 1.25x
- 1x, selected
- 0.75x
- 0.5x
- Chapters
- descriptions off, selected
- captions settings, opens captions settings dialog
- captions off, selected
This is a modal window.
Beginning of dialog window. Escape will cancel and close the window.
End of dialog window.
This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.
C. Ola Landgren, MD, PhD, professor of medicine, chief, Division of Myeloma, Department of Medicine, University of Miami, Miller School of Medicine; director, Sylvester Myeloma Institute; co-leader, Translational and Clinical Oncology Program, Paul J. DiMare Endowed Chair in Immunotherapy, Sylvester Comprehensive Cancer Center, discusses an investigation of tocilizumab (Actemra) prophylaxis in patients with relapsed or refractory multiple myeloma treated with teclistamab-cqyv (Tecvayli), elranatamab-bcmm (Elrexfio), or talquetamab-tgvs (Talvey).
Related Content:
